RE: Biotech Stocks Burn A Hole In Big Pharma's Pocket; 202020 Aug 2020 09:01
"For Bristol-Myers Squibb (BMY), the addition of Celgene gives it access to another blockbuster cancer drug, Revlimid. In 2018, Revlimid generated $9.67 billion in sales, accounting for 63% of Celgene revenue. Revlimid patents will soon expire, however."
Perhaps they could look to augment its efficacy by improving its precision and thus extending/renewing the patent?